123 related articles for article (PubMed ID: 8881790)
21. Compliance with follow-up and prognosis among patients with thin melanomas.
Kittler H; Weitzdorfer R; Pehamberger H; Wolff K; Binder M
Eur J Cancer; 2001 Aug; 37(12):1504-9. PubMed ID: 11506957
[TBL] [Abstract][Full Text] [Related]
22. Is there increased risk of local and in-transit recurrence following sentinel lymph node biopsy?
Cerovac S; Mashhadi SA; Williams AM; Allan RA; Stanley PR; Powell BW
J Plast Reconstr Aesthet Surg; 2006; 59(5):487-93. PubMed ID: 16631558
[TBL] [Abstract][Full Text] [Related]
23. Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.
Matheson JA; Te Marvelde L; Mailer S; Speakman D; Spillane J; Henderson MA; Gyorki DE
Melanoma Res; 2017 Feb; 27(1):43-49. PubMed ID: 27753732
[TBL] [Abstract][Full Text] [Related]
24. Risk factors associated with local and in-transit recurrence of cutaneous melanoma.
Stucky CC; Gray RJ; Dueck AC; Wasif N; Laman SD; Sekulic A; Pockaj BA
Am J Surg; 2010 Dec; 200(6):770-4; discussion 774-5. PubMed ID: 21146019
[TBL] [Abstract][Full Text] [Related]
25. [After-care of melanoma. 8 years' experience using the Mainz model].
Schramm P
Z Hautkr; 1988 Oct; 63(10):816-21. PubMed ID: 3070988
[TBL] [Abstract][Full Text] [Related]
26. Late recurrence of malignant melanoma presenting as small bowel intussusception.
Rampone B; Roviello F; Marrelli D; De Marco G; Rossi S; Corso G; Cerullo G; Pinto E
Dig Dis Sci; 2006 Jun; 51(6):1047-8. PubMed ID: 16865566
[No Abstract] [Full Text] [Related]
27. Desmoplastic, neural transforming and neurotropic melanoma: a review of 45 cases.
Smithers BM; McLeod GR; Little JH
Aust N Z J Surg; 1990 Dec; 60(12):967-72. PubMed ID: 2268214
[TBL] [Abstract][Full Text] [Related]
28. Evolving treatment strategies in thin cutaneous head and neck melanoma: 1 institution's experience.
Jaber JJ; Clark JI; Muzaffar K; Ruggiero FP; Feustel PJ; Frett MJ; Zender CA
Head Neck; 2011 Jan; 33(1):7-12. PubMed ID: 20848424
[TBL] [Abstract][Full Text] [Related]
29. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma.
Baker JJ; Meyers MO; Frank J; Amos KD; Stitzenberg KB; Ollila DW
Am J Surg; 2014 Apr; 207(4):549-54. PubMed ID: 24674829
[TBL] [Abstract][Full Text] [Related]
30. [Prognosis of malignant melanoma following dissection regional lymph node metastases].
Sprakel B; Stenschke F; Unnewehr M; Ladas A; Senninger N
Chirurg; 2003 Jan; 74(1):55-60. PubMed ID: 12552406
[TBL] [Abstract][Full Text] [Related]
31. Staging work-up and post-treatment surveillance of patients with melanoma.
Olson JA; Jaques DP; Coit DG; Hwu WJ
Clin Plast Surg; 2000 Jul; 27(3):377-90, viii. PubMed ID: 10941559
[TBL] [Abstract][Full Text] [Related]
32. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.
Seegenschmiedt MH; Keilholz L; Altendorf-Hofmann A; Urban A; Schell H; Hohenberger W; Sauer R
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):607-18. PubMed ID: 10348291
[TBL] [Abstract][Full Text] [Related]
33. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.
Shields CL; Shields JA; Gündüz K; Cater J; Mercado GV; Gross N; Lally B
Arch Ophthalmol; 2000 Nov; 118(11):1497-507. PubMed ID: 11074806
[TBL] [Abstract][Full Text] [Related]
34. Guidelines for management of malignant melanoma of the lower limb--based on a study of long-term behaviour.
Lewis MH; Hill JT; Leopold JG; Hughes LE
Clin Oncol; 1982 Dec; 8(4):341-9. PubMed ID: 7168927
[No Abstract] [Full Text] [Related]
35. [In a patient, surgically treated for isolated primary melanoma, what is the risk of recurrence? How to evaluate this risk?].
Gautier MS
Ann Dermatol Venereol; 1995; 122(5):336-48. PubMed ID: 8572477
[No Abstract] [Full Text] [Related]
36. Late recurrence of malignant melanoma. Analysis of 168 patients.
Crowley NJ; Seigler HF
Ann Surg; 1990 Aug; 212(2):173-7. PubMed ID: 2375648
[TBL] [Abstract][Full Text] [Related]
37. Malignant melanoma: significance of disease-free interval.
Yarnold JR; Cochrane JP
Br J Radiol; 1980 Nov; 53(635):1068-70. PubMed ID: 7426933
[TBL] [Abstract][Full Text] [Related]
38. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year.
Damude S; Hoekstra-Weebers JE; Francken AB; Ter Meulen S; Bastiaannet E; Hoekstra HJ
Ann Surg Oncol; 2016 Sep; 23(9):2762-71. PubMed ID: 27194552
[TBL] [Abstract][Full Text] [Related]
39. [Descriptive analysis of cutaneous recurrence patterns in patients with melanoma].
Marcoval J; Ferreres JR; Penín RM; Piulats JM; Caminal JM; Fabra A
Actas Dermosifiliogr; 2011 Dec; 102(10):791-6. PubMed ID: 21658662
[TBL] [Abstract][Full Text] [Related]
40. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group.
Dicker TJ; Kavanagh GM; Herd RM; Ahmad T; McLaren KM; Chetty U; Hunter JA
Br J Dermatol; 1999 Feb; 140(2):249-54. PubMed ID: 10233217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
